Synapse - Works

Results (115370)

NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53(WT)) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed

Meeting Abstract

Wong, M. K. K.; Burgess, M. A.; Chandra, S.; Fecher, L. A.; Gaudy-Marqueste, C.; Silk, A. W.; Hanna, G. J.; Lebbe, C.; Quéreux, G.; Rabinowits, G.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases

Meeting Abstract

Betof Warner, A.; Postow, M. A.; Panageas, K.; Smithy, J. W.; Schoenfeld, A. J.; Wolchok, J. D.; Shoushtari, A. N.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001)

Meeting Abstract

Mansfield, A. S.; Goodrich, A.; Foster, N. R.; Savvides, P.; Villaruz, L. C.; Forde, P. M.; Raghav, K. P. S.; Romesser, P. B.; Feldman, D.; Cao, L.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R)

Meeting Abstract

Forde, P. M.; Nowak, A. K.; Hughes, B. G. M.; Kok, P. S.; Brown, C.; Sun, Z.; Anagnostou, V.; O'Byrne, K.; Yip, S.; Cook, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer

Meeting Abstract

Johnson, M. L.; Henry, J. T.; Spira, A. I.; Battiste, J.; Alnahhas, I.; Ahluwalia, M. S.; Barve, M. A.; Edenfield, W. J.; Nam, D. H.; Eathiraj, S.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM)

Meeting Abstract

Davar, D.; Ikeguchi, A.; Buchbinder, E. I.; Shoushtari, A. N.; Seedor, R. S.; Bernicker, E.; Weiss, S. A.; Daniels, G. A.; Panella, T. J.; Ryan, H. F.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) for patients with pleural metastases from thymic malignancies

Meeting Abstract

Rimner, A.; Huang, J.; Pagano, A.; Ginsberg, M. S.; Chang, J. C.; Riely, G. J.; Simone, C. B.; Gomez, D. R.; Shepherd, A.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma

Meeting Abstract

Follows, G.; Burke, J. M.; Grosicki, S.; Chen, C.; Sanna, A.; Roeker, L. E.; Yi, S.; Munir, T.; de la Cruz, F.; Ferrant, E.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent

Meeting Abstract

Kumar, S.; Bachier, C. R.; Cavo, M.; Corradini, P.; Delforge, M.; Janowski, W.; Lesokhin, A. M.; Mina, R.; Paris, L.; Rosiñol, L.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma

Meeting Abstract

Eyre, T. A.; Thompson, P.; Wierda, W. G.; Šimkovič, M.; Grosicki, S.; Jurczak, W.; Wang, Y.; Móciková, H.; Zinzani, P. L.; Tam, C. S. L.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save